Marketed by: Dr. Reddy’s Laboratories (Hyderabad, India)
Compared to: Revatio (Pfizer, Inc)
Indication: The FDA has approved Dr. Reddy’s Laboratories’ abbreviated new drug application for Sildenafil Tablets, a bioequivalent version of Revatio. It is indicated for the treatment of pulmonary arterial hypertension in adults. It improves exercise ability and delays worsening of clinical symptoms. The recommended dose is 20 mg 3 times per day, administered 4 to 6 hours apart. It is not recommended for patients who take nitrates or other products containing sildenafil.
Dosage Form: Tablets: 20 mg
For More information: www.drreddys.com
Phenytoin Oral Suspension
Marketed by: Greenstone LLC (Peapack, NJ)
Compared to: Dilantin 125 (Pfizer, Inc)
Indication: Greenstone LLC, a subsidiary of Pfizer, Inc, introduced an authorized generic of Dilantin 125. Phenytoin Oral Suspension is indicated for the control of tonic-clonic and psychomotor seizures. The recommended dose for adults is 1 teaspoon 3 times daily. Dosage should be adjusted as needed to suit patient needs; however, dosing should not exceed 5 teaspoons daily. It is indicated for use in adults, children, and the elderly, though dosage adjustments may be necessary for elderly and pediatric patients.
Dosage Form: Oral suspension: 125 mg/5 mL
For More Information: http://greenstonellc.com
Pramipexole Dihydrochloride Tablets
Marketed by: Aurobindo Pharma, Ltd (Hyderabad, India)
Compared to: Mirapex (Boehringer Ingelheim)
Indication: Aurobindo Pharma, Ltd, has released Pramipexole Dihydrochloride Tablets, a generic equivalent of Boehringer Ingelheim’s Mirapex. Pramipexole Dihydrochloride is indicated for the treatment of Parkinson’s disease. It is available in several strengths, and dosing should be adjusted based on patients’ needs. Tablets can be taken with or without food; administration with food is recommended if patients experience nausea. Pramipexole Dihydrochloride has a sedating effect, and can lead to falling asleep during daily activities, including driving.
Dosage Form: Tablets: 0.125, 0.25, 0.5, 0.75, 1, and 1.5 mg
Methylphenidate Hydrochloride Extendedrelease Capsules
Marketed by: Teva Pharmaceuticals (North Wales, PA)
Compared to: Metadate CD (UCB Inc)
Indication: Teva Pharmaceuticals has introduced Methylphenidate Hydrochloride Extended-Release Capsules, a generic equivalent to Metadate CD. It is indicated for the treatment of attention-deficit/hyperactivity disorder symptoms, including lack of attention to details, lack of sustained attention, and poor organizational skills. The recommended dosage is 20 mg once daily before a morning meal. The dosage may be increased or decreased in 10-mg increments, but patients should not take more than 60 mg per day.
Dosage Form: Capsules: 10, 20, 30, 40, 50, and 60 mg
For More Information: www.tevagenerics.com